InvestorsHub Logo
Followers 38
Posts 2971
Boards Moderated 0
Alias Born 10/07/2012

Re: The Other Guy post# 111993

Thursday, 02/14/2013 12:55:03 PM

Thursday, February 14, 2013 12:55:03 PM

Post# of 346286

It may have been this part of Shan's statement that caused the concern:

"In light of this data, as well as other recent developments in the treatment of pancreatic cancer, we are actively evaluating the next steps for advancing the bavituximab pancreatic program," said Joseph Shan.

I think what he is refering to is the fact that soon it will be Celgene's Abraxane in conjunction with Gemcitabine that will become SOC for this indication, so based on their subset analysis and this new development they will devise their plans accordingly. JMO.

GLTA

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News